

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
16 January 2025 (16.01.2025)



(10) International Publication Number
WO 2025/010504 A1

(51) International Patent Classification:

C07C 219/08 (2006.01) *A61K 48/00* (2006.01)
A61K 9/51 (2006.01) *C07C 219/06* (2006.01)
A61K 39/00 (2006.01) *C12N 15/10* (2006.01)
A61K 47/18 (2017.01) *C12N 15/88* (2006.01)

(21) International Application Number:

PCT/CA2024/050922

(22) International Filing Date:

10 July 2024 (10.07.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

3205968	10 July 2023 (10.07.2023)	CA
3216061	11 October 2023 (11.10.2023)	CA
63/622,281	18 January 2024 (18.01.2024)	US

(71) Applicant: **PROVIDENCE THERAPEUTICS HOLDINGS INC.** [CA/CA]; 120, 8832 Blackfoot Trail SE, Calgary, Alberta T2J 3J1 (CA).

(72) Inventors: **GOPALAKRISHNA PANICKER, Rajesh Krishnan**; c/o Providence Therapeutics Holdings Inc., 120, 8832 Blackfoot Trail SE, Calgary, Alberta T2J 3J1 (CA). **KARPOV, Yury**; c/o Providence Therapeutics Holdings Inc., 120, 8832 Blackfoot Trail SE, Calgary, Alberta T2J 3J1 (CA). **MARTIN OROZCO, Natalia**; c/o Providence Therapeutics Holdings Inc., 120, 8832 Blackfoot Trail SE, Calgary, Alberta T2J 3J1 (CA).

(74) Agent: **ROBIC AGENCE PI S.E.C. / ROBIC IP AGENCY LP**; 630 Rene-Levesque Blvd W, 20th Floor, Montréal, Québec H3B 1S6 (CA).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

(54) Title: DIESTER LIPIDS, LIPID NANOPARTICLE CONTAINING DIESTER LIPIDS, AND FORMULATIONS THEREOF





Figure 3

(57) Abstract: Provided is a diester lipid compound of Formula (I) or a pharmaceutically acceptable salt thereof. The compound can be used to obtain lipid nanoparticles. In some embodiments, the lipid nanoparticle can comprise (a) from about 40 to about 100 mol % of the compound of Formula (I); (b) from 0 to about 10 mol % of a neutral lipid; (c) from 0 to about 50 mol % of a helper lipid; (d) from 0 to about 5 mol % of a polymer-conjugated lipid; and (e) from 0 to about 5 mol % of a hydrophobic component; wherein the mol % are based on the total lipids present in the nanoparticle. (I)

[Continued on next page]



WO 2025/010504 A1

HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*